Cargando…
KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study
BACKGROUND: KLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis. RESULTS: Qualitative methylation-specif...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913797/ https://www.ncbi.nlm.nih.gov/pubmed/29690914 http://dx.doi.org/10.1186/s13048-018-0407-y |
_version_ | 1783316605727408128 |
---|---|
author | El Sherbini, Mustafa A. Mansour, Amal A. Sallam, Maha M. Shaban, Emtiaz A. Shehab ElDin, Zeinab A. El-Shalakany, Amr H. |
author_facet | El Sherbini, Mustafa A. Mansour, Amal A. Sallam, Maha M. Shaban, Emtiaz A. Shehab ElDin, Zeinab A. El-Shalakany, Amr H. |
author_sort | El Sherbini, Mustafa A. |
collection | PubMed |
description | BACKGROUND: KLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis. RESULTS: Qualitative methylation-specific PCR (MSP) results did not show statistically significant differences in patient group samples (normal and tumor) where all samples were positive only for the unmethylated-specific PCR except for two malignant samples that were either doubly positive (serous carcinoma) or doubly negative (Sertoli-Leydig cell tumor) for the two MSP tests. However, KLK10 exon 3 unmethylated PCR product concentration (ng/μl) showed statistically significant differences in benign and malignant patient group samples; mean ± SD (n): tumor: 0.077 ± 0.035 (14) and 0.047 ± 0.021 (15), respectively, p-value = 0.011; and normal: 0.094 ± 0.039 (7) and 0.046 ± 0.027 (6), respectively, p-value = 0.031. Moreover, ROC curve analysis of KLK10 exon 3 unmethylated PCR product concentration in overall patient group samples showed good diagnostic ability (AUC = 0.778; p-value = 0.002). Patient survival (living and died) showed statistically significant difference according to preoperative serum CA125 concentration (U/ml); median (n): 101.25 (10) and 1252 (5), respectively, p-value = 0.037, but not KLK10 exon 3 unmethylated PCR product concentration (ng/μl) in overall malignant patient samples; mean ± SD (n): 0.042 ± 0.015 (14) and 0.055 ± 0.032 (7), p-value = 0.228. CONCLUSION: To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. Taken into account the limitations in our study (small sample size and semi-quantitative PCR product analysis) further studies are strongly recommended. |
format | Online Article Text |
id | pubmed-5913797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59137972018-04-30 KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study El Sherbini, Mustafa A. Mansour, Amal A. Sallam, Maha M. Shaban, Emtiaz A. Shehab ElDin, Zeinab A. El-Shalakany, Amr H. J Ovarian Res Research BACKGROUND: KLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis. RESULTS: Qualitative methylation-specific PCR (MSP) results did not show statistically significant differences in patient group samples (normal and tumor) where all samples were positive only for the unmethylated-specific PCR except for two malignant samples that were either doubly positive (serous carcinoma) or doubly negative (Sertoli-Leydig cell tumor) for the two MSP tests. However, KLK10 exon 3 unmethylated PCR product concentration (ng/μl) showed statistically significant differences in benign and malignant patient group samples; mean ± SD (n): tumor: 0.077 ± 0.035 (14) and 0.047 ± 0.021 (15), respectively, p-value = 0.011; and normal: 0.094 ± 0.039 (7) and 0.046 ± 0.027 (6), respectively, p-value = 0.031. Moreover, ROC curve analysis of KLK10 exon 3 unmethylated PCR product concentration in overall patient group samples showed good diagnostic ability (AUC = 0.778; p-value = 0.002). Patient survival (living and died) showed statistically significant difference according to preoperative serum CA125 concentration (U/ml); median (n): 101.25 (10) and 1252 (5), respectively, p-value = 0.037, but not KLK10 exon 3 unmethylated PCR product concentration (ng/μl) in overall malignant patient samples; mean ± SD (n): 0.042 ± 0.015 (14) and 0.055 ± 0.032 (7), p-value = 0.228. CONCLUSION: To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. Taken into account the limitations in our study (small sample size and semi-quantitative PCR product analysis) further studies are strongly recommended. BioMed Central 2018-04-24 /pmc/articles/PMC5913797/ /pubmed/29690914 http://dx.doi.org/10.1186/s13048-018-0407-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research El Sherbini, Mustafa A. Mansour, Amal A. Sallam, Maha M. Shaban, Emtiaz A. Shehab ElDin, Zeinab A. El-Shalakany, Amr H. KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title | KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title_full | KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title_fullStr | KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title_full_unstemmed | KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title_short | KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study |
title_sort | klk10 exon 3 unmethylated pcr product concentration: a new potential early diagnostic marker in ovarian cancer? - a pilot study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913797/ https://www.ncbi.nlm.nih.gov/pubmed/29690914 http://dx.doi.org/10.1186/s13048-018-0407-y |
work_keys_str_mv | AT elsherbinimustafaa klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy AT mansouramala klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy AT sallammaham klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy AT shabanemtiaza klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy AT shehabeldinzeinaba klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy AT elshalakanyamrh klk10exon3unmethylatedpcrproductconcentrationanewpotentialearlydiagnosticmarkerinovariancancerapilotstudy |